An FDA application for TAR-200 to treat BCG-unresponsive high-risk non-muscle-invasive bladder cancer is under real-time ...

The New Drug Application for TAR-200 is supported by results from the Phase IIb SunRISe-1 study, which demonstrated an 83.5% complete response in patients with Bacillus Calmette-Guérin-unresponsive ...

A phase 3 trial of Johnson & Johnson's TAR-200 therapy in bladder cancer has failed to show efficacy, although the company is still confident in the potential of the programme. The SunRISe-2 study ...

Johnson & Johnson seeks FDA approval for TAR-200, targeting BCG-unresponsive high-risk NMIBC with CIS, through the Real-Time Oncology Review program. Phase 2b SunRISe-1 trial data showed an 83.5% ...

Cetrelimab is under clinical development by Johnson & Johnson and currently in Phase III for Muscle Invasive Bladder Cancer (MIBC). According to GlobalData, Phase III drugs for Muscle Invasive Bladder ...

(UroToday.com) The 2024 SUO annual meeting included a session on non muscle invasive bladder cancer, featuring a presentation by Dr. Ashish Kamat discussing BCG unresponsive cancer in 2024.

(UroToday.com) The 2024 Society of Urologic Oncology (SUO) annual meeting held in Dallas, between December 3 and December 6, 2024, was host to the Bladder Cancer Session II. Dr. Mamta Parikh discussed ...

XOMA Royalty Corporation's portfolio includes riskier assets, impacting its stability. Find out why XOMA stock’s high-risk ...

The antibody-drug conjugate showed a higher objective response rate but failed to meet the primary OS endpoint in patients with pretreated advanced urothelial carcinoma. Physician’s choice of ...